Clinical Trials Sponsored by Acorda Therapeutics

Total 6391 results

Acorda Therapeutics

Terminated

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

Refractory Epilepsy

United States
Acorda Therapeutics

Completed

Study of Oral Fampridine-SR in Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Terminated

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Epilepsy

United States
Acorda Therapeutics

Completed

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

Healthy

United States
Acorda Therapeutics

Completed

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

Asthma

United States
Acorda Therapeutics

Completed

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Ischemic Stroke

United States
Acorda Therapeutics

Completed

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Cerebral Palsy (CP)

United States
Acorda Therapeutics

Completed

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Muscle Spasticity | Spinal Cord Injury

United States, Canada
Acorda Therapeutics

Completed

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Parkinson's Disease

United States
Acorda Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. (MILESTONE℠)

Post-Ischemic Stroke

United States, Canada
Acorda Therapeutics

Completed

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

Parkinson Disease

United States
Acorda Therapeutics

Completed

A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure

Heart Failure

United States
Acorda Therapeutics

Completed

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

Migraine

United States
Acorda Therapeutics

Completed

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial (TQT)

Spasticity

United States
Acorda Therapeutics

Completed

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Poland, Spain
Acorda Therapeutics

Completed

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Idiopathic Parkinson's Disease

United States, Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Serbia, Spain, United Kingdom
Acorda Therapeutics

Completed

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes (SPAN-PD™)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Poland, Spain
Acorda Therapeutics

Terminated

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. (MILESTONE℠)

Post-ischemic Stroke

United States, Canada
Acorda Therapeutics

Completed

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

Idiopathic Parkinson's Disease

United States, Italy, Serbia, United Kingdom
Acorda Therapeutics

Completed

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Migraine

United States
Acorda Therapeutics

Completed

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

Muscle Spasticity | Spinal Cord Injury

United States, Canada
Acorda Therapeutics

Completed

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

Epilepsy

United States
Acorda Therapeutics

Completed

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

Parkinson's Disease

United States
Acorda Therapeutics

Completed

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Smoking

United States
Acorda Therapeutics

Completed

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure (GGF2-1101-1)

Heart Failure

United States
Acorda Therapeutics

Completed

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Acorda Therapeutics

Completed

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Renal Insufficiency

United States
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Multiple Sclerosis

United States, Canada
Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
Acorda Therapeutics
Syneos Health

Terminated

Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

Spasticity Due to Cerebral Palsy

United States
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Idiopathic Parkinson Disease

United States, Canada, United Kingdom
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Abuse Potential

Canada
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Acorda Therapeutics
PRA Health Sciences

Completed

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Multiple Sclerosis, Acute Relapsing

United States
University of Miami
Acorda Therapeutics

Completed

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

Parkinson's Disease

United States
Johns Hopkins University
Acorda Therapeutics

Completed

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Neuromyelitis Optica | Transverse Myelitis | Idiopathic Transverse Myelitis | Myelitis NOS

United States
Acorda Therapeutics
PRA Health Sciences

Completed

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (M22)

Multiple Sclerosis

United States
University of Florida
Acorda Therapeutics

Completed

Dalfampridine and Gait in Spinocerebellar Ataxias

Spinocerebellar Ataxias Type 1 | Spinocerebellar Ataxias Type 2 | Spinocerebellar Ataxias Type 3 | Spinocerebellar Ataxias Type 6

United States
Neuro-Ophthalmologic Associates, PC
Acorda Therapeutics

Completed

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Ampyra)

Non Arteritic Ischemic Optic Neuropathy

United States
Washington University School of Medicine
Acorda Therapeutics

Completed

Ampyra for Optic Neuritis in Multiple Sclerosis

Multiple Sclerosis | Optic Neuritis

United States
Brown, Theodore R., M.D., MPH
Acorda Therapeutics

Completed

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Multiple Sclerosis

United States
Acorda Therapeutics
Prometrika, LLC; BCS Consulting, Inc.

Completed

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Azora Therapeutics Australia Pty Ltd

Completed

Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Australia
Azora Therapeutics Australia Pty Ltd

Active, not recruiting

Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Plaque Psoriasis | Nail Psoriasis

Australia
D'Youville College
University at Buffalo; Acorda Therapeutics

Completed

Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis

Multiple Sclerosis

3

Subscribe